Apple Inc users will be able to opt out of the company reviewing their conversations with voice assistant Siri under measures announced on Wednesday to address concerns over how it holds and uses audio recordings.
Source:: Reuters – Business News
Newswire
- [ March 6, 2025 ] Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer Newsmakers
- [ March 3, 2025 ] BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia Newsmakers
- [ February 24, 2025 ] PepGen (NASDAQ: PEPG) Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights Newsmakers
- [ February 18, 2025 ] ScanTech AI (NASDAQ: STAI) Announces Initiative to Combat Contraband in Correctional Facilities Across the Americas Newsmakers
- [ February 18, 2025 ] ProPhase Labs (NASDAQ: PRPH) hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports Newsmakers
- [ February 5, 2025 ] Cumberland Pharmaceuticals (NASDAQ: CPIX) Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Newsmakers
- [ February 5, 2025 ] Pasithea Therapeutics (NASDAQ: KTTA) Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer Newsmakers
- [ January 30, 2025 ] BigBear.ai (NYSE: BBAI)Awarded Prime IDIQ Contract for U.S. Department of Navy’s SeaPort Next Generation (NxG) Newsmakers
- [ January 30, 2025 ] ScanTech AI Systems (NASDAQ: STAI) Deploys Its Advanced AI-Driven Security Screening Technology to Protect Multiple Nuclear Power Plants Operated by Ontario Power Generation Newsmakers
- [ January 30, 2025 ] Kazia Therapeutics (NASDAQ: KZIA) announces launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.